within Pharmacolibrary.Drugs.ATC.V;

model V09EX03
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0003333333333333333,
    adminDuration  = 600,
    adminMass      = 740 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0007,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V09EX03</td></tr><td>route:</td><td>inhalation</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Xenon-133 (133Xe) is a radioactive isotope of xenon gas used primarily as a diagnostic agent in nuclear medicine for imaging pulmonary ventilation and blood flow in the lungs. It is inhaled by the patient and its distribution in the lung is detected by gamma cameras. Xenon-133 is not approved for therapeutic use and is used only in diagnostic settings.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for inhaled 133Xe gas in healthy adult humans as estimated from literature and physical properties of inert noble gases with high oil/gas partition coefficients. Data on PK parameters are limited and most models assume rapid lung uptake and elimination primarily by exhalation.</p><h4>References</h4><ol><li><p>Prohovnik, I, et al., &amp; Lucas, LR (1997). Physostigmine reversal of scopolamine-induced hypofrontality. <i>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</i> 17(2) 220–228. DOI:<a href=\"https://doi.org/10.1097/00004647-199702000-00012\">10.1097/00004647-199702000-00012</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9040502/\">https://pubmed.ncbi.nlm.nih.gov/9040502</a></p></li><li><p>Petersen, KA, et al., &amp; Olesen, J (2005). BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. <i>Clinical pharmacology and therapeutics</i> 77(3) 202–213. DOI:<a href=\"https://doi.org/10.1016/j.clpt.2004.10.001\">10.1016/j.clpt.2004.10.001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15735614/\">https://pubmed.ncbi.nlm.nih.gov/15735614</a></p></li><li><p>O&#x27;Riordan, TG, et al., &amp; Smaldone, GC (1995). Delivery and distribution of aerosolized cyclosporine in lung allograft recipients. <i>American journal of respiratory and critical care medicine</i> 151(2 Pt 1) 516–521. DOI:<a href=\"https://doi.org/10.1164/ajrccm.151.2.7842214\">10.1164/ajrccm.151.2.7842214</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7842214/\">https://pubmed.ncbi.nlm.nih.gov/7842214</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V09EX03;
